Providing Support in the Workplace to Address Substance Abuse and Mental Health with Clark Lagemann Avidon Health TRANSCRIPT
Download PDFJul 20, 2022
Clark Lagemann is the CEO of Avidon Health which is helping organizations support employees as they recover from the disruption of COVID and adjust to the reconfiguration of the workplace. While many people are leaving their jobs for more income, Avidon is finding that employees are also seeking resources to address...
Jul 20, 2022
Clark Lagemann is the CEO of Avidon Health which is helping organizations support employees as they recover from the disruption of COVID and adjust to the reconfiguration of the workplace. While many people are leaving their jobs for more income, Avidon is finding that employees are also seeking resources to address...
Jun 22, 2022
Greg Sturmer is the Co-Founder and CEO of Elysium Therapeutics and rethinking how to overcome the challenges of opioid abuse and addiction by reformulating the drug itself. Blending an understanding of chemistry and human behavior, Elysium questions why it takes 70 years for an opioid to lose half its potency and what...
Opioid Modifications and Innovations to Guard Against Abuse and Overdoses with Greg Sturmer Elysium Therapeutics TRANSCRIPT
Download PDFJun 22, 2022
Greg Sturmer is the Co-Founder and CEO of Elysium Therapeutics and rethinking how to overcome the challenges of opioid abuse and addiction by reformulating the drug itself. Blending an understanding of chemistry and human behavior, Elysium questions why it takes 70 years for an opioid to lose half its potency and what...
Developing Serotonin-3 Receptor Blocker to Treat Alcohol Use Disorder with Bill Stilley Adial Pharmaceuticals TRANSCRIPT
Download PDFMay 23, 2022
Bill Stilley is the CEO and President of Adial Pharmaceuticals, which is focused on developing medicinal therapies for the treatment and prevention of addiction. Their first drug is a genetically targeted drug to treat alcohol use disorder, otherwise known as alcoholism.
Bill explains, "Yes, in the end, a lot of...